IN2012DN02869A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02869A IN2012DN02869A IN2869DEN2012A IN2012DN02869A IN 2012DN02869 A IN2012DN02869 A IN 2012DN02869A IN 2869DEN2012 A IN2869DEN2012 A IN 2869DEN2012A IN 2012DN02869 A IN2012DN02869 A IN 2012DN02869A
- Authority
- IN
- India
- Prior art keywords
- peptide
- specifically
- humanized antibodies
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention futher provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24021809P | 2009-09-06 | 2009-09-06 | |
PCT/IL2010/000731 WO2011027349A1 (en) | 2009-09-06 | 2010-09-06 | Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02869A true IN2012DN02869A (en) | 2015-07-24 |
Family
ID=43648941
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2869DEN2012 IN2012DN02869A (en) | 2009-09-06 | 2010-09-06 |
Country Status (12)
Country | Link |
---|---|
US (3) | US8680241B2 (en) |
EP (2) | EP3366308A1 (en) |
JP (1) | JP5781514B2 (en) |
KR (1) | KR101831229B1 (en) |
CN (1) | CN102740877B (en) |
AU (1) | AU2010290844B2 (en) |
BR (1) | BR112012004983A2 (en) |
CA (1) | CA2772567A1 (en) |
IN (1) | IN2012DN02869A (en) |
MX (1) | MX2012002768A (en) |
RU (1) | RU2596925C2 (en) |
WO (1) | WO2011027349A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3177366A1 (en) | 2006-08-10 | 2008-02-21 | Roy C. Levitt | Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors |
WO2016062734A1 (en) * | 2014-10-24 | 2016-04-28 | F. Hoffmann-La Roche Ag | Vh-vl-interdomain angle based antibody humanization |
AU2016210582B2 (en) | 2015-01-22 | 2020-01-30 | Ramakrishna Reddy Isanaka | Peptide for treating inflammatory diseases |
ES2965292T3 (en) * | 2015-07-09 | 2024-04-12 | Inst Nat Sante Rech Med | Lentiviral vector expressing membrane-anchored or secreted antibody |
MX2018011739A (en) * | 2016-03-31 | 2018-12-19 | Immutrix Therapeutics Inc | Method for extracorporeal treatment of preeclampsia and related disorders. |
CN118459590A (en) * | 2018-08-01 | 2024-08-09 | 感应检查疗法公司 | Anti-BTN 3A antibodies and their use in the treatment of cancer or infectious disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
US7488476B2 (en) | 1998-11-05 | 2009-02-10 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases |
IL142709A0 (en) * | 1998-11-05 | 2002-03-10 | Hadasit Med Res Service | Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
WO2003057527A2 (en) * | 2001-12-31 | 2003-07-17 | L.A.S. Trust, Ein 02/6105365 | Recreational vehicle |
EP1619521A1 (en) | 2004-07-22 | 2006-01-25 | IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. | Capacitive transmitter electrode |
CU23504A1 (en) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | PEPTIDES AND DERIVATIVES APL TYPE OF HSP60 AND PHARMACEUTICAL COMPOSITIONS |
EP1844074B1 (en) | 2005-02-03 | 2013-04-24 | Antitope Limited | Human antibodies and proteins |
EP1928497A2 (en) * | 2005-08-24 | 2008-06-11 | Cell-Matrix, Inc. | Combination therapies for inhibiting integrin-extracellular matrix interactions |
PT1989544E (en) | 2006-03-02 | 2011-09-26 | Antitope Ltd | T cell assays |
WO2007137279A2 (en) | 2006-05-22 | 2007-11-29 | Board Of Regents, The University Of Texas System | Herv-k antigens, antibodies, and methods |
WO2008114733A1 (en) * | 2007-03-16 | 2008-09-25 | Kyowa Hakko Kirin Co., Ltd. | Anti-claudin-4 antibody |
CN101903402B (en) * | 2007-11-13 | 2014-07-16 | 泰华生物制药美国公司 | Humanized antibodies against TL1A |
US8642041B2 (en) | 2009-03-30 | 2014-02-04 | Protab Ltd. | Adenylyl cyclase-associated protein (CAP1) and uses thereof as a target for immuno-modulation |
WO2012174338A2 (en) * | 2011-06-15 | 2012-12-20 | Glaxosmithkline Llc | Method of selecting therapeutic indications |
-
2010
- 2010-09-06 IN IN2869DEN2012 patent/IN2012DN02869A/en unknown
- 2010-09-06 MX MX2012002768A patent/MX2012002768A/en not_active Application Discontinuation
- 2010-09-06 KR KR1020127008389A patent/KR101831229B1/en active IP Right Grant
- 2010-09-06 US US13/392,548 patent/US8680241B2/en not_active Expired - Fee Related
- 2010-09-06 AU AU2010290844A patent/AU2010290844B2/en not_active Ceased
- 2010-09-06 JP JP2012527448A patent/JP5781514B2/en not_active Expired - Fee Related
- 2010-09-06 CN CN201080050177.2A patent/CN102740877B/en not_active Expired - Fee Related
- 2010-09-06 BR BR112012004983-6A patent/BR112012004983A2/en not_active Application Discontinuation
- 2010-09-06 CA CA2772567A patent/CA2772567A1/en not_active Abandoned
- 2010-09-06 WO PCT/IL2010/000731 patent/WO2011027349A1/en active Application Filing
- 2010-09-06 RU RU2012106891/10A patent/RU2596925C2/en not_active IP Right Cessation
- 2010-09-06 EP EP18161381.1A patent/EP3366308A1/en not_active Withdrawn
- 2010-09-06 EP EP10813428.9A patent/EP2475383A4/en not_active Withdrawn
-
2014
- 2014-01-31 US US14/169,996 patent/US20140170138A1/en not_active Abandoned
-
2017
- 2017-04-19 US US15/491,377 patent/US20170218056A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2475383A1 (en) | 2012-07-18 |
AU2010290844B2 (en) | 2015-04-09 |
WO2011027349A1 (en) | 2011-03-10 |
RU2596925C2 (en) | 2016-09-10 |
CA2772567A1 (en) | 2011-03-10 |
JP2013503852A (en) | 2013-02-04 |
EP2475383A4 (en) | 2013-07-17 |
CN102740877A (en) | 2012-10-17 |
RU2012106891A (en) | 2013-10-27 |
MX2012002768A (en) | 2012-06-28 |
EP3366308A1 (en) | 2018-08-29 |
US20170218056A1 (en) | 2017-08-03 |
CN102740877B (en) | 2015-01-14 |
KR20120060224A (en) | 2012-06-11 |
US20140170138A1 (en) | 2014-06-19 |
KR101831229B1 (en) | 2018-02-22 |
BR112012004983A2 (en) | 2021-02-23 |
US8680241B2 (en) | 2014-03-25 |
JP5781514B2 (en) | 2015-09-24 |
AU2010290844A1 (en) | 2012-03-15 |
US20120156201A1 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02869A (en) | ||
NZ596540A (en) | Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide | |
NZ597692A (en) | Anti-IGF antibodies | |
MX2009009450A (en) | He4 monoclonal antibodies and methods for their use. | |
NZ601793A (en) | Methods and compositions for diagnosis and treatment of cancer | |
WO2005103083A3 (en) | Anti-cd38 human antibodies and uses therefor | |
NZ601583A (en) | Novel rabbit antibody humanization methods and humanized rabbit antibodies | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
GB201112429D0 (en) | Antigen-binding proteins with increased FcRn binding | |
NZ593550A (en) | ANTI-Siglec-15 ANTIBODY | |
MX2009012949A (en) | Humanized antibodies which bind to aî² (1-42) globulomer and uses thereof. | |
UA111818C2 (en) | ANTIBODY AGAINST CSF-1R | |
MX2012000841A (en) | Optimizing the production of antibodies. | |
NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
NZ597023A (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
MX2010010387A (en) | Bcr-complex-specific antibodies and methods of using same. | |
MX2011008843A (en) | Humanized antibodies that bind to cd19 and their uses. | |
NZ607969A (en) | Cd33 binding agents | |
MX2012011768A (en) | Antibodies that bind human cd27 and uses thereof. | |
NZ612312A (en) | Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota | |
UA96141C2 (en) | Neutralising antibody having specificity for human il-6 | |
EA201490677A1 (en) | BONDING ANTIGEN CD27L PROTEINS | |
MX2011008759A (en) | Means and methods for manufacturing highly pure neurotoxin. | |
EA201070539A1 (en) | NEW ANTIBODIES SPECIFIC TO β-AMYLOID PEPTIDES, AND THEIR USE AS DIAGNOSTIC OR MEDICINES | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof |